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I-Chieh Chen1, Wei-Fan Chiang2,3, Shyun-Yeu Liu2, Pei-Fen Chen1 and Hung-Che Chiang1,4,5*Abstract
Background: Sirtuins (SIRT1-7) are a family of NAD-dependent deacetylases, which play an important role in
regulating cancer tumorigenesis; however, their role in oral cancer has been controversial. SIRT3 is localized in the
mitochondria, where it deacetylates and activates several enzymes involved in cellular redox balance and defense
against oxidative damage.
Results: We found that compared with normal human oral keratinocytes (HOK), SIRT3 is highly expressed in oral
squamous cell carcinoma (OSCC) cell lines, but the enzymatic deacetylation is significantly reduced. We also
sequenced the entire coding region of SIRT3 and found the same mutation in 2 different OSCC cell lines. This point
mutation is located in close proximity to the active site of deacetylase in the SIRT3 protein, and reduces the overall
enzymatic efficiency of deacetylation. Furthermore, up-regulation of SIRT3 inhibited the cell growth of OSCCs and
decreased the levels of basal reactive oxygen species (ROS) in both OSCC lines. To verify that the SIRT3 sequence
variation was associated with oral carcinogenesis, we sequenced the SIRT3 gene from 21 OSCC patients, and 5 of
the 21 patients (23.8%) carried the heterozygous missense mutation, p.Val208Ile. The heterozygous missense
mutation in these patients was present in gremlin DNA isolated from both normal and tumor tissues.
Conclusions: Our findings provide a valuable insight into the potential role of SIRT3 in the development of oral
squamous cell carcinoma, by showing that a non-synonymous point mutation in SIRT3 contributes to reduced
catalytic activity of the protein and affects redox balance in OSCCs.
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Oral cancer is the eighth most common cancer in men
worldwide, and its incidence is increasing [1]. Oral squa-
mous cell carcinoma (OSCC) accounts for >90% of oral
cancers and can develop from oral precancerous lesions
such as leukoplakias and erythroplakias [1,2]. A signifi-
cant risk factor for the development of oral cancer is the
chewing of areca nuts, which is a widespread habit
throughout Southeast Asia [3,4]. Previous studies have
revealed that areca nut extract (ANE) and other ingredi-
ents induce oxidative stress, elicit the formation of react-
ive oxygen species (ROS), and activate a stress response
in cells [5-7]. ROS, such as superoxide (O2
-) or hydrogen* Correspondence: hcchiang@nhri.org.tw
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reproduction in any medium, provided the orperoxide (H2O2), are constantly produced during meta-
bolic processes in all living species. ROS can react with
DNA, proteins, and lipids, and play important roles in
many physiological and pathophysiological conditions,
such as diabetes, neurodegenerative diseases, cancer, and
aging [8]. Some chemical reactions involving ROS have
considerable potential to damage genomic integrity [9].
The mitochondrial respiratory chain is one of the major
sources of cellular ROS generation (~90% of ROS) [8].
In this cycle, electrons can escape the electron transport
chain and react with molecular oxygen, leading to the
generation of superoxides. ROS are involved in both the
initiation and promotion of multistage carcinogenesis.
Therefore, an understanding of mitochondrial regulation
of ROS generation can provide important insights into
the contribution of ROS to oral carcinogenesis. Recently,
it was reported that several members of the sirtuin fam-
ily (SIRT1-7), the human homologues of the Sir2 gene in
yeast, play an important role in carcinogenesis [10]. Thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tide (NAD+)-dependent protein deacetylases [11], and
their enzymatic activity is regulated by the ratio of NAD+
to NADH; high NAD+ levels activate sirtuins, and con-
versely, high NADH levels inhibit sirtuin activity [12].
Sirtuins regulate multiple cellular processes and physio-
logical states, including the amount of oxidative stress,
genomic stability, cell survival, development, metabolism,
aging, and the longevity of organisms ranging from yeasts
to humans [13-15]. Of the 7 SIRT analogues, SIRT1,
SIRT6, and SIRT7 are primarily localized in the nucleus,
whereas SIRT2 is in the cytoplasm, and SIRT3, SIRT4,
and SIRT5 are localized in the mitochondria [16]. SIRT3 is
synthesized as an inactive protein, is activated by matrix
peptidase [17,18], and mediates regulation of oxidative
stress [19-21]. In addition, SIRT3-deficient animals exhibit
a striking global acetylation of mitochondrial proteins,
while no significant changes in protein acetylation are
observed in SIRT4−/− and SIRT5−/− mitochondria [22].
These findings indicate that SIRT3 is a major mitochon-
drial deacetylase. Acetylation by SIRT3 controls the
enzymatic activity of mitochondrial proteins such as long-
chain acyl-CoA dehydrogenase [19] in the fatty acid oxida-
tion pathway, 3-hydroxy-3-methylglutaryl CoA synthase 2
in the ketone body synthesis pathway [23], ornithine
transcarbamylase [24] in the urea cycle, isocitrate de-
hydrogenase 2 [21], and manganese superoxide dismutase
[20,25] in the antioxidant system. Furthermore, the en-
zymatic activities of these enzymes are regulated by adap-
tive changes in acetylation in response to environmental
stimuli [26]. In addition, a key role of SIRT3 in mitochon-
dria is to serve as a mitochondrial localized tumor sup-
pressor via its ability to inhibit mitochondrial ROS
production [27-29]. Specifically, SIRT3 deficiency alone is
sufficient to stimulate primary mouse embryo fibroblasts
withMyc and/or RAS to form tumors in xenograft models.
These data indicate that deletion of SIRT3 replaces the
need for the loss of tumor suppressor required for trans-
formation of primary cells by an oncogene. Additionally,
studies have shown that germline SIRT3−/− mice display
increased levels of cellular ROS [20,21,27,30,31] and
impaired cellular respiration in different tissues after
prolonged fasting [19]. In contrast, SIRT3 overexpression
in vivo suppresses cellular ROS levels [29]. In addition,
these SIRT3−/− mice display higher rates of high fat diet-
induced obesity, insulin resistance, hyperlipidemia, and
steatohepatitis [32]. The etiology of such defects may be
found in the ability of SIRT3 to enhance cellular levels of
antioxidants [19-21,24,33]. Although ROS levels were in-
creased in SIRT3−/− cells, these cells also contain detoxifi-
cation enzymes that should scavenge the increased ROS.
Thus, in accordance with the studies, cells lacking SIRT3
may have dysfunctional coordination of both mitochon-
drial respiratory chain and detoxification enzymes, whichcan result in aberrant and potentially damaging levels of
ROS. Accordingly, this suggests that SIRT3 may regulate
the initiation and progression of cancer by controlling the
cellular redox balance. Although some investigators have
suggested a particular role for SIRT3, these reports under-
score the complexity of the biologic functions of SIRT3,
which may differ according to the tissue of origin or can-
cer type. However, to our knowledge, the role of SIRT3 in
regulating antioxidant defenses has not been investigated
in oral squamous cell carcinoma. Therefore, the objective
of the current study was to elucidate the role of SIRT3 in
regulating cellular redox balance in OSCC.Results
Variable levels of SIRT3 expression and its activity
To examine whether expression of SIRT3 was different
between normal primary human oral keratinocytes (HOK)
and OSCCs, we examined the mRNA and protein levels in
2 OSCC cell lines (HSC-3 and OECM1) and compared
those cells with HOK cells (Figure 1A). We found that
SIRT3 was slightly overexpressed in both OSCC cell lines
compared to expression in HOK, although the SIRT3
mRNA levels were lower in OSCC cell lines. To under-
stand the function of SIRT3, we examined its enzymatic
activity. For this purpose, we isolated the mitochondria
fractions from HOK cells and OSCCs. Subsequently,
endogenous SIRT3 was immunoprecipitated from mito-
chondrial fractions and tested for deacetylase activity. Sur-
prisingly, we found that both OSCC cell lines had
drastically lower levels of SIRT3 activity compared with
HOK cells. The enzyme activities of SIRT3 in OECM-1
and HSC-3 were decreased by ~65% and 61%, respectively
(Figure 1B). Because SIRT3 controls the enzymatic activity
of mitochondrial proteins by deacetylation, we wanted to
examine SIRT3-mediated deacetylation of its target pro-
teins, such as long-chain acyl coenzyme A dehydrogenase
(LCAD) in the fatty acid oxidation pathway, and manga-
nese superoxide dismutase (SOD2) in the antioxidant
system. We first examined the ability of SIRT3 to bind tar-
get proteins by co-immunoprecipitation. As shown in
Figure 1C, western blotting detected SOD2 and LCAD in
SIRT3 immunoprecipitates from mitochondrial extracts of
normal cells and OSCCs. We next determined the acetyl-
ation levels of SOD2 and LCAD by western blotting, and
found that the acetylation level of SOD2 was significantly
lower in HOK cells compared with OSCCs. Furthermore,
the acetylation level of LCAD was also slightly higher in
OSCCs cultured under basal conditions. These results in-
dicated that SIRT3 expression was slightly higher in
OSCCs than in normal cells. However, the enzyme activity
of SIRT3 was significantly reduced in OSCCs, leading to
decreased deacetylation of mitochondrial proteins, which






















































































































































Figure 1 Variable levels of SIRT3 expression and its activity are noted in normal cells (HOK) and OSCCs. (A) RT-PCR and western blotting
reveal the expression levels of SIRT3 in HOK and OSCC cell lines. (B) Specific activities of SIRT3 in HOK and OSCC cell lines were determined by
enzyme assay. Each data point represents the mean ± SD from at least 3 independent experiments (mean ± SD). (C) Mitochondrial extracts from
HOK, OECM1, and HSC3 cells were immunoprecipitated by using a SIRT3 antibody and analyzed by western blot using antibodies against SOD2,
IDH2, and acetylated-lysine (Ac-K).
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Because the enzyme activity of SIRT3 was decreased in
OSCCs, we tested whether sequence variations existed
in the SIRT3 gene that could be correlated with de-
creased deacetylase activity in OSCCs. We sequenced
the entire coding region of SIRT3 in HOK cells and the
2 OSCC cell lines. From alignment of the SIRT3 gene
DNA sequence in HOK cells and OSCC cell lines, we
found 5 and 2 positions of genetic variation in the SIRT3
coding region in OECM-1 and HSC-3 cells, respectively
(Figure 2). As shown in Figure 2, these genetic variations
in SIRT3 were present within the conserved catalytic
deacetylase domain of SIRT3 [34] and could therefore
affect its enzymatic activity. Furthermore, the non-
synonymous point mutation at nucleotide position 622,
which led to the change of valine at position 208 to iso-
leucine (V208I), was present in both OECM-1 and HSC-3 cells. This change was located in close proximity to
the deacetylase active site of SIRT3, and might be re-
sponsible for the reduced catalytic efficiency. To test for
this possibility, we expressed recombinant WT SIRT3,
SIRT3-V208I, SIRT3-P345R, and catalytically inactive
SIRT3-H248A in Escherichia coli and tested their
deacetylase activity in vitro. A steady-state kinetic ana-
lysis of SIRT3 activity was performed, and the initial
rates of fluorescence release were measured as a func-
tion of NAD+ concentration. The resulting saturation
curves were fitted to the Michaelis-Menten equation,
and the Vmax and KM kinetic parameters were compared
among WT SIRT3, SIRT3-V208I, SIRT3-P345R, and
catalytically inactive SIRT3-H248A. We observed a 20%
increase in the KM value for NAD
+ in SIRT3-V208I,
compared to WT SIRT3, indicating more NAD+ was re-
























Figure 2 Schematic of SIRT3 protein and sequencing analyses identifying variations in the coding region of SIRT3 in HOK and OSCC
cell lines.
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KM, we also observed a 19% reduction in the Vmax for
NAD+ in SIRT3-V208I, compared with WT SIRT3. In
addition, we observed a 29% reduction in the SIRT3-
V208I Vmax for the peptide substrate, compared to WT
SIRT3, but there was no change in the KM for the pep-
tide substrate (Figure 3B and Table 1). However, there was
almost no affect on the enzyme activity of SIRT3-P345R
(Table 1). These results suggest that in 3 independent
enzyme preparations, the SIRT3-V208I mutation reduced
catalytic efficiency by 37% compared to the catalytic
efficiency of WT SIRT3 (Table 1). Together, theseNAD+ (mM)


















Figure 3 Steady-state kinetic analyses of SIRT3 activity. The rates of ac
peptide substrate concentration (B), as determined by fluorescence intensi
least 3 independent experiments (mean ± SD).observations demonstrated that the mutant SIRT3-V208I
had reduced enzyme efficiency, and this could partially ex-
plain why OSCC cell lines with the SIRT3-V208I mutation
have lower SIRT3 activity than HOK cells.
SIRT3 gain of function regulates proliferation and ROS
levels
The in vitro kinetics assays demonstrated that recombin-
ant SIRT3-V208I shows reduced enzymatic activity com-
pared to WT SIRT3, indicating that the SIRT3-V208I
mutant might contribute to the development of OSCCs.
We thus sought to determine the effect of transientlyB  
Peptide substrate (nM)



















tivity were measured as a function of NAD+ concentration (A) or
ty of each sample. Each data point represents the mean ± SD from at
Table 1 Summary of SIRT3 steady-state kinetic analyses
SIRT3
WT V208I P345R H248Y
NAD+ Vmax (pmole/min/mg) 16.03 ± 0.02 12.14 ± 0.06 15.94 ± 0.14 1.08 ± 0.16
KM (mM) 0.88 ± 0.01 1.07 ± 0.03 0.88 ± 0.07 N.D.
Catalytic efficiency (Vmax/KM) 18.21 11.35 18.11 N.D.
Peptide Vmax (pmole/min/mg) 17.5 ± 0.69 12.5 ± 0.03 17.32 ± 0.45 1.32 ± 0.11
KM (mM) 147.3 ± 12.4 153.4 ± 17.5 146.8 ± 10.8 54.2 ± 14.0
Catalytic efficiency (Vmax/KM) 0.11 0.07 0.12 0.02
Rates of activity were measured as a function of NAD+ concentration or peptide substrate concentration, as measured by fluorescence intensity;
n = 3 independent experiments (mean ± SD).
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tagged SIRT3 expressing vector. We observed a nearly
2- to 3-fold induction of flag-tagged SIRT3, relative
to endogenous levels (Figure 4A). Furthermore,
overexpression of SIRT3 decreased basal ROS levels
by ~30% and 48% in HSC-3 and OECM-1, respectively
(Figure 4A). We also confirmed the enzymatic activity
of SIRT3 after transfection with expression vector.
OSCC cell lines were transiently transfected with or
without WT SIRT3, and SIRT3 activity was measured.
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Figure 4 ROS levels and cell proliferation are regulated by SIRT3 in O
overexpressing flag-tagged SIRT3 and their relative fluorescence after incubati
OSCCs. OECM-1 and HSC-3 cell lines were transiently transfected with or with
cell lines. Each data point represents the mean ± SD from at least 3 independ
difference (*, p < 0.05) compared to control.lines showed a mild increase in SIRT3 activity when
transfected with the flag-tagged SIRT3-expressing vec-
tor (Figure 4B). Next, we examined whether SIRT3 had
a role in cell proliferation by transiently expressing
SIRT3 in OSCC cell lines. Exogenously expressed WT
SIRT3 significantly decreased cell growth compared to
the growth of vector transfected cells in both cell lines
(Figure 4C). These data indicated that SIRT3 could pos-
sess tumor suppressor functions in OSCC cell lines, in
addition to its previously described role in inhibiting
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SCCs. (A) Western blotting of whole cell lysates isolated from cells
on with DHE. C: control; T: transfected cells. (B) Relative activity of SIRT3 in
out flag-tagged SIRT3. (C) Cell proliferation of SIRT3-overexpressing OSCC
ent experiments (mean ± SD). The asterisk indicates a significant
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OSCC is a complex disease resulting from interactions
between genetic and environmental factors [35,36]. Its de-
velopment is a multistep process requiring the accumula-
tion of multiple genetic alterations. These alterations are
influenced by a patient’s genetic predisposition as well as
by environmental factors, including tobacco, alcohol,
chronic inflammation, and viral infection [35]. Because ex-
ogenously expressed WT SIRT3 produced inhibition of cell
growth in OSCC cell lines, we tested whether variability in
the SIRT3 gene was correlated with increased susceptibility
for developing oral squamous cell carcinoma. We obtained
reliable forward and reverse DNA sequencing results from
amplified fragments of the SIRT3 gene obtained from 21
OSCC patients. We found that 4 of the 21 patients (19%,
OSCC_31, 32, 39, 482) had a G to T transition at nucleo-
tide 477 in exon 2 of SIRT3; this was a silent mutation that
did not produce a change in the amino acid sequence. An-
other 5 patients (23.8%, OSCC_30, 31, 32, 39, 482) carried
a G to A transition at nucleotide 622 in exon 3; this was a
missense mutation resulting in the replacement of valine at
residue 208 with isoleucine (p.Val208Ile). To validate our
results and discriminate whether the detected SIRT3 muta-
tions were present in the germ-line cells or somatic cells,Figure 5 Sequence chromatograms of DNA isolated from a patient w
OSCC_32. Left, heterozygous mutation in normal DNA; Right, heterozygous m
(p.Val208Ile) carried by patient OSCC_32.Left, heterozygous mutation in norma
Right, predominance of expression of the mutated allele in cDNA synthesizedwe performed targeted exon sequencing of DNA isolated
from tumor and normal cells of patients. Patients carried
s.477G >T or c.622G >A as a heterozygous mutation in
both normal and tumor cells. This finding indicated
they had a germ-line genetic alteration of the SIRT3 gene
(Figure 5), resulting in a V208I mutation in the mature
protein. Sequence analysis of cDNA synthesized from
tumor RNA revealed that the mutant allele was predomin-
antly expressed in the tumor (Figure 5). Together, these
results indicate that OSCC patients carried a germ-line
mutation in the SIRT3 gene, represented by one single-
base change, which introduced a non-synonymous point
mutation that resulted in reduced catalytic activity of the
SIRT3 protein. This could partially explain how patients
with a V208I mutation in the SIRT3 enzyme may have an
enhanced genetic susceptibility for developing OSCC.
SIRT3 activity in OSCC patients
A sequence analysis conducted with OSCC patients
demonstrated that variability in the SIRT3 gene was cor-
related with increased susceptibility for developing oral
squamous cell carcinoma. To obtain additional evidence
for the effect of SIRT3 activity in OSCC patients, we an-
alyzed the SIRT3 enzyme activity of normal subjects andith OSCC. (A) Region harboring the s.477G > A mutation in patient
utation in tumor DNA. (B) Region harboring the c.622G> A mutation
l DNA; Middle, heterozygous mutation in tumor DNA;
from OSCC_32 tumor RNA.
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tissue from healthy individuals after tooth extractions, and
10 pairs of matched normal and tumor tissue samples from
21 OSCC patients. We then immunopurified endogenous
SIRT3 proteins from these tissue samples and assayed for
enzymatic activity. Surprisingly, we found that the SIRT3
proteins from tumor and normal tissues of patients
(OSCC_30, 31, 32, 39, 482) who carried c.622G >A had
drastically lower levels of SIRT3 activity compared tissues
from normal individuals (Figure 6). The enzyme activity of
SIRT3 from the 5 OSCC patients (OSCC_24, 26, 28, 490,
495) who didn’t carry this missense mutation was higher
than activity in patients with the SIRT3 V208I mutation,
but it remained lower than activity in normal individuals.
These results indicate that the V208I mutation in the
SIRT3 enzyme was capable of reducing the enzyme’s activ-
ity, and that decreasing SIRT3 activity may increase
susceptibility to the development of oral squamous
cell carcinoma.
Discussion
In this study, we demonstrated that SIRT3 regulates cellu-
lar ROS, and this regulation has important implications
for the growth of oral squamous cell carcinoma cells. It
has been previously shown that SIRT3 contributes to cell
survival by modulating oxidative stress pathways [37,38].
Our study showed that SIRT3 was slightly overexpressed
in both OSCC cell lines compared with HOK cells, but
the enzyme activity of SIRT3 was significantly reduced in
OSCCs, which could be caused by genetic change. We
found that increased activity SIRT3 in oral squamous cell
carcinoma contributes to decreased ROS levels and in-
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Figure 6 SIRT3 enzyme activity of normal individuals and OSCC patie
N, normal tissue and T, tumor tissue. Each data point represents the meanentire coding region of SIRT3 and found a non-
synonymous point mutation at nucleotide position 622 in
the SIRT3 coding region in both OSCC cell lines. Signifi-
cantly, mutation of this position in the recombinant pro-
tein SIRT3-V208I was responsible for a 37% reduction of
catalytic efficiency compared to WT SIRT3. This idea was
further validated by the finding that in 5 of 21 OSCC
patients, the SIRT3 mutation carried c.622G >A as a het-
erozygous mutation in both normal and tumor tissues, in-
dicating that these patients had a germ-line genetic
alteration of the SIRT3 gene. Additionally, we also deter-
mined the SIRT3 activity in 5 normal subjects and 10
OSCC patients (with or without c.622G >A) and found
that all the OSCC patients had lower SIRT3 activity than
normal subjects, and activity was especially lower in
patients who carried the heterozygous missense mutation
(c.622G > A). Taken together, these data indicate that
SIRT3 may function as a tumor suppressor in OSCC cell
lines by regulating cellular ROS levels and decreasing
SIRT3 activity, and also may increase susceptibility to the
development of oral squamous cell carcinoma. Our find-
ings are consistent with previous work showing that
SIRT3 functions as a tumor suppressor through regulation
of ROS [27]. Kim et al. found that elevated ROS in the ab-
sence of SIRT3 increased genomic instability, promoting a
tumor-permissive environment. We propose that SIRT3
might play a role in promoting tumorigenesis by altering
cellular ROS levels.
In this study, we found that SIRT3 was slightly
overexpressed in both OSCC cell lines compared with
HOK cells, but the SIRT3 enzyme activity in OECM-1 and
HSC-3 was decreased by ~65% and 61%, respectively. We








































nts who did or did not carry the c.622G > A mutation of SIRT3.
± SD from at least 3 independent experiments (mean ± SD).
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tation was located in close proximity to the deacetylase
active site of SIRT3 in OECM-1 and HSC-3 cells. How-
ever, the enzyme activity of recombinant protein (SIRT3-
V208I) was responsible for a ~37% reduction in catalytic
efficiency compared to WT SIRT3. These data showed
that overexpression of SIRT3 did not result in greater
deacetylase activity in OSCCs, and that SIRT3 activity
might be regulated by mechanisms such as post-
translational modifications. Recently, it was discovered
that SIRT3 is required for PGC-1α-mediated differenti-
ation of brown adipose tissue in a manner that is
dependent on the level of an estrogen-related receptor
α (ERRα) [33,39]. The transcription coactivator PGC-
1α could be regulating the SIRT3 gene involved in en-
ergy metabolism [40]. Thus, upon cellular stress, e.g.,
an increase in ROS or nutrient deprivation, human
SIRT3 transcription might be stimulated [40], and the
protein translocated to the mitochondrial inner mem-
brane. There, SIRT3 could deacetylate and thereby
activate the target enzymes and play a key role in
modulating mitochondrial activities and the regulation
of many pathways. However, current studies of SIRT3
have mainly focused on its cellular localization and
identification of its substrates; the mechanism regulat-
ing SIRT3 function and activity remains unclear. We
now know that the N-terminal extension of SIRT3 con-
tains a mitochondria targeting signal peptide. During
import of SIRT3 into the mitochondrial matrix, the
protein is proteolytically cleaved at position 101 and
thus enzymatically activated [18]. It has been postu-
lated that the proteolytically shortened N-terminal re-
gion and the C-terminal extension form a module that
might regulate access of substrate proteins to the active
site [41]. Six phosphorylated serine residues (out of a
total of 8 possible sites) between positions 101 and 118
may have been identified in a high-resolution mass
spectrometry-based phosphoproteome analysis [42].
Therefore, it is possible that phosphorylation modu-
lates the enzymatic activity of SIRT3 in mitochondria
by regulating interaction of the N-terminal region with
the catalytic domain. However, the biological relevance
or influence on SIRT3 function has not yet been ana-
lyzed and more studies will be needed to understand
the mechanism for regulation of SIRT3 activity.
In this study, we hypothesized that reduced SIRT3 ac-
tivity might lead to an increase in cellular ROS signaling,
thereby enhancing tumorigenesis. We identified the en-
tire coding region of SIRT3 in HOK cells and 2 OSCC
cell lines, and found a correlation between a genetic
change at nucleotide position 622 in the SIRT3 gene in
OECM-1 and HSC-3 cells. We tested for the possibility
of a functional impact of the non-synonymous point
mutation (V208I) in the SIRT3 protein. We usedAcArgGlyLys(Ac)AMC peptide as the substrate and de-
termined deacetylase enzyme activity by measuring
fluorescence intensity. As shown in Figure 3 and Table 1,
the KM value and Vmax of SIRT3-V208I for NAD
+ were
1.07±0.03 mM and 12.14±0.06 pmole/min/mg, respect-
ively. The KM v and Vmax kinetic parameters were com-
pared between WT SIRT3 and SIRT3-V208I, indicating
a 20% increase in the KM and a 19% reduction in the
Vmax for NAD
+ in SIRT3-V208I. Moreover, we observed
a 29% reduction in the SIRT3-V208I Vmax for the pep-
tide substrate compared to WT SIRT3, but there was no
change in the KM for the peptide substrate. These results
indicate that the V208I lies within the conserved sirtuin
catalytic deacetylase domain, and the mutation from val-
ine to isoleucine reduced SIRT3 enzyme efficiency by
both increasing the KM for NAD
+ and reducing the
Vmax. Our data were consistent with a model in which
reduction in SIRT3 enzymatic activity associated with
the V208I mutation plays a pathogenic role in oral squa-
mous cell carcinoma. Interestingly, it has been reported
that genetic polymorphism in the SIRT3 gene is linked
to longevity [43,44] and metabolic syndrome [32,45-48].
Similar results of V208I mutation had reported by Eric
Verdin’s group [32] using different assay procedures.
Verdin et al. used [3H-histone H4 peptide] as a substrate
and measured rates of activity by using an organic-
soluble radioactive signal. They found an 18% increase
in the KM and a 19% reduction in the Vmax for NAD
+ in
SIRT3-V208I, compared to WT SIRT3, respectively.
Their observations demonstrate that the SIRT3-V208I
mutation reduced 34% catalytic efficiency and could in-
crease susceptibility to developing the metabolic syn-
drome. However, less is currently known about the
genetic polymorphism of SIRT3 in tumor cells. In the
present study with 21 OSCC patients, we found that 4
(19%) had s.477G > T of SIRT3, a silent mutation produ-
cing no change in the amino acid sequence. Additionally,
5 patients (23.8%) carried c.622G > A of SIRT3, a mis-
sense mutation resulting in the replacement of valine at
residue 208 with isoleucine (p.Val208Ile). As shown in
Figure 5, the OSCC_32 patient carried either s.477G > T
or c.622G > A as a heterozygous mutation in both nor-
mal and tumor tissues, indicating there was a germ-line
genetic alteration of the SirT3 gene. The findings indi-
cate that the SIRT3 +622A allele is positively associated
with development of OSCC. This led to the reduction of
catalytic efficiency in OSCCs, and promoted tumorigen-
esis by altering cellular ROS levels.
The exact role of mutant SIRT3 in tumorigenesis is
poorly understood. Recently, several groups have pro-
vided evidence that SIRT3 is required to suppress
tumorigenesis, and to induce stress-mediated cell death
in tumors, including breast cancer, colorectal carcinoma,
osteosarcoma, and leukemia [27-29,49,50]. Furthermore,
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mouse embryonic fibroblasts in the direction of oncogenic
transformation, and that SIRT3−/− mouse embryonic fibro-
blasts exhibit stress-induced genomic instability [27].
While the activation of both oncogenes, Myc and Ras, is
needed to transform an immortalized fibroblast into a
tumor-forming cell, genetic deletion of SIRT3 reduced that
requirement to only the activation of either Myc or Ras.
Thus, SIRT3 functions as a tumor suppressor [51]. In
addition, overexpression of SIRT3 is shown to decrease
tumorigenesis in xenografts, even when induction of SIRT3
occurs after tumor ignition [29]. In our study, we deter-
mined the endogenous SIRT3 activity from 10 pairs of
matched normal and tumor tissue samples obtained from
OSCC patients. We found that the SIRT3 proteins from
OSCC patients had significantly lower deacetylase activity
than SIRT3 proteins from normal subjects, thus suggesting
that a decrease of SIRT3 activity may increase susceptibility
to tumor development. However, current studies of SIRT3
have mainly focused on its cellular localization and identifi-
cation of its substrates; the molecular mechanism regulat-
ing SIRT3 activity remains unclear.
In this study, we began to investigate the potential role
of SIRT3 in regulating cellular redox balance in oral
squamous cell carcinoma and studied how SIRT3 is in-
volved in oral carcinogenesis. However, the sample size
of this study was small, and a larger number of OSCC
patients must be evaluated for SIRT3 mutation to reach
definitive conclusions about the role of this gene in the
development of oral squamous cell carcinoma.
Conclusions
In this study, we found that SIRT3 gene mutations were
present in both OECM-1 and HSC-3 cell lines, and in
OSCC patients, supporting the hypothesis that SIRT3
may act as a tumor suppressor and regulate the initi-
ation and progression of cancer by controlling cellular
redox balance. Our studies indicate that the germline
mutation of the SIRT3 gene potentially plays a critical
role in tumorigenesis and may contribute to increased
susceptibility for the development of OSCC. Future
studies screening a larger number of OSCC patients for
SIRT3 mutations to highlight important genetic alter-
ations may help identify useful targets for personalized
cancer therapy and more successful cancer treatment.
Methods
Cell culture and reagents
HOK cells used in this study were cultured in oral kera-
tinocyte growth medium (ScienCell, Carlsbad, CA, USA).
Cells were cultured in a 37°C incubator filled with 5% CO2
and routinely passaged at 90% confluence. Two human
OSCC cell lines, HSC-3 (tongue carcinoma), and OECM-
1 (gingival carcinoma), were also used in this study. HSC-3 cells were cultured in Dulbecco’s modified Eagle’s
medium with 2 mM glutamine; OECM-1 cells were
maintained in RPMI 1640 medium. Each culture medium
was supplemented with 10% fetal bovine serum and
100 units/mL of penicillin and streptomycin (Invitrogen,
Camarillo, CA, USA). All OSCC cells were maintained at
37°C in a humidified atmosphere of 5% CO2.
Genomic DNA, RNA isolation, and quantitative
real-time PCR
For gene expression analysis, pairs of tumor and normal
marginal tissues were obtained from 21 OSCCs. Frozen
tissues were stored in liquid nitrogen at −196°C until use.
Genomic DNA obtained from cultured cells and human
tissue was subjected to bisulfite treatment using the
EpiTect Bisulfite kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Total RNA obtained
from cultured cells and human tissue was extracted using
TRIzol reagent (Invitrogen). cDNA was then reverse-
transcribed and amplified by PCR using a Transcriptor
First Strand cDNA Synthesis kit (Roche Diagnostics,
Mannheim, Germany). Quantitative RT-PCR was carried
out using the FastStart Universal SYBR Green Master
(Roche) on an Applied Biosystems ABI 7900 RealTime
PCR System (Applied Biosystems, Foster City, CA,
USA). The oligonucleotide primers for human SIRT3
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)




gene expression level was normalized using GAPDH as an
internal reference gene, and the average relative change
was calculated using 3–5 determinations by relative quan-
tification, applying the delta-delta cycle threshold method.
This study was approved by the Institutional Review Board
(IRB) of the Department of Oral and Maxillofacial Surgery
of Chi-Mei Medical, Liouying, Taiwan (EC-1000202-R1).
Plasmid construction and infection
The human SIRT3 coding region (GeneBank: NM_012239)
was amplified by polymerase chain reaction (PCR) using
the forward primer 5′-TTCGAACCATGGCGTTCTGGG
GTTGG-3′, which introduced a Nsp V site, and 5′-
CTCGAGCTATTTGTCTGGTCCATCAAGCTTCCC-3′,
which introduced a XhoI site, under the following condi-
tions: denaturing for 30 sec at 94°C, annealing for 30 sec at
62°C, and elongation for 1 min at 72°C for 35 cycles. The
full-length of SIRT3 was subcloned into the constitutive
mammalian expression vector, pCMV-Tag 2B (Stratagene,
Amsterdam, Netherlands), and verified by DNA sequen-
cing. Transfected cells were seeded in 6-cm cell dishes at
5 × 105 cells/dish and transfected with pCMV2B-SIRT3 or
empty vector using Lipofectamine reagent (Invitrogen),
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were used for further cell proliferation assays.Cell proliferation assay
Transfected cells were seeded in 96-well culture plates at
1 × 104 cells/well and incubated for 72 h. Cell proliferation
was assessed using the MTT assay according to the manu-
facturer’s recommendations (Roche).Mitochondria isolation and immunoprecipitation
Mitochondria were isolated from cultured cells by using a
mitochondria isolation kit (Pierce Biotechnology, Inc.,
Rockford, IL, USA) following the manufacturer’s protocol.
Isolated mitochondria were lysed with RIPA buffer, and
then underwent direct western blot analysis or immunopre-
cipitation. Then, 2 mg of protein from samples (total lysates
or mitochondrial extracts) was used for immunoprecipita-
tion with a Pierce® Crosslink IP Kit (Pierce) following the
manufacturer’s protocol, and analyzed by western blot.Western blot analysis
Cells were lysed directly in RIPA buffer and adjusted for
protein concentration using the BCA protein assay kit
(Bio-Rad, Hercules, CA, USA). Lysates were resolved by
10% SDS-PAGE and then transferred to PVDF mem-
branes. The membranes were blocked and incubated
with specific antibodies against SIRT3 (Cell Signaling),
actin (Sigma-Aldrich, St. Louis, MO, USA), GAPDH
(Santa Cruz Biotechnology, Santa Cruz, CA, USA),
SOD2 (Epitomics, San Diego, CA, USA), LCAD (Pierce),
and acetylated-lysine (Cell Signaling) antibodies. Proteins
were visualized by enhanced chemiluminescence using
an ECL-Plus detection system (Perkin Elmer-NEN,
Courtaboeuf, France).ROS measurement
Cellular ROS was detected using the fluorescent
dye dihydroethidium (DHE) obtained from Vigorous
(Vigorous, Beijing, China) according to a previous study
[52]. Cells were transiently transfected with or without
flag-tagged SIRT3 and cultured in 6-well plates for 24 h.
The cells were then washed with PBS and labeled with
DHE (5 μmol/L dissolved in 1% DMSO) in the culture
plates at 37°C for 30 minutes in PBS. Culture plates
were placed on ice to stop the labeling, trypsinized, and
resuspended in ice-cold PBS. Samples were analyzed
using a flow cytometer (BD FACS Calibur, BD Biosci-
ences, San Jose, CA, USA). The mean fluorescence
intensity (MFI) of 10,000 cells was analyzed in each
sample and corrected for auto-fluorescence from
unlabeled cells.Enzyme activity assay
SIRT3 proteins from total lysates of cultured cells and hu-
man tissue were concentrated using a Pierce® Crosslink IP
Kit (Pierce), according to the manufacturer’s recommen-
dations. Protein concentration was determined using the
Bio-Rad protein assay kit (Bio-Rad). The enzyme activity
assay for SIRT3 was performed in 50 μL of deacetylase
buffer (4 mM, MgCl2, 0.2 mM dithiothreitol, 50 mM
Tris–HCl, pH 8.5) containing 25 μL of SIRT3 proteins
(10 ng/μL), 2 mM NAD+, and 25 μL of 1 mM fluorogenic
peptide substrate AcArgGlyLys(Ac)AMC (R&D systems,
Minneapolis, MN, USA). Deacetylation reactions were
conducted at 37°C for 30 minutes, and stopped by adding
50 μL of stop solution made by combining recombinant
mouse trypsin 3/PRSS3 AMC (R&D systems) and nico-
tinamide (Sigma-Aldrich) to final concentrations of
0.2 ng/μL and 4 mM, respectively. The assays were then
incubated at room temperature for 15 minutes, and read
at excitation and emission wavelengths of 380 nm and
460 nm, respectively in endpoint mode. The activity
was measured with a SpectraMax M2 microplate reader
(Molecular Devices Corporation, Sunnyvale, CA, USA).
Statistical analysis
The data are reported as the mean ± S.D. of at least 3 inde-
pendent experiments. The P values for linear trend of
mRNA expression levels were analyzed using the t test
(slope estimate) in simple linear regression models. The
difference was considered statistically significant at the
level of P < 0.05 or P < 0.01.
Consent
Written informed consent was obtained from the
patient for publication of this report and any accom-
panying images.Abbreviations
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